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Gas-phase structures of noncovalent complexes between the glycopeptide antibiotics vanco-
mycin, eremomycin, ristocetin, and pseudo aglyco-ristocetin and the cell-wall mimicking
peptides N-acetyl-D-Alanyl-D-Alanine, N-acetyl-Glycyl-D-Alanine, and N,N9-di-acetyl L-
Lysyl-D-Alanyl-D-Alanine have been probed by hydrogen/deuterium (H/D) exchange using
ND3 as reagent gas. The noncovalent complexes were transferred from solution to the vacuum
using electrospray ionization. The H/D exchange of the solvent-free ions was studied in a
Fourier transform ion cyclotron resonance mass spectrometer. The H/D exchange behavior of
the free antibiotics and the free peptides were compared with the exchange observed for the
antibiotic–peptide complexes. A general increase was found in the degree of deuterium
incorporation upon complex formation with the ligand, which indicates that the peptide
binding makes more sites on the antibiotic capable of taking part in the H/D exchange. Apart
from H/D exchange, adduct formation with ND3 was observed, but only for the singly
protonated peptides and the doubly protonated [ristocetin1N-acetyl-D-Alanyl-D-Alanine].
This marked difference in chemical reactivity of closely related systems such as [ristocetin1N-
acetyl-Glycyl-D-Alanine] and [ristocetin1N-acetyl-D-Alanyl-D-Alanine] indicates that the
gas-phase structures of these noncovalent complexes are quite sensitive to small changes in the
primary structures of the peptides. The gas-phase structures of the antibiotic–peptide
complexes are probably different from the solution-phase structures, with the peptides no
longer bound to the characteristic solution-phase binding pockets of the antibiotics. (J Am
Soc Mass Spectrom 1998, 9, 1255–1266) © 1998 American Society for Mass Spectrometry
Because many bacteria have become resistant topenicillin, vancomycin group antibiotics nowa-days play an important role against bacterial
infections. Vancomycin itself is a natural product pro-
duced by microorganism as a secondary metabolite and
was first discovered in the mid-1950s. It has been in use
as an antibiotic since 1959. The structure of vancomycin
antibiotic was however not described until the 1980s [1,
2]. The structures of two related glyco-peptide antibiot-
ics, i.e., ristocetin [3] and eremomycin [4], were also
characterized in the 1980’s. Figure 1 shows the struc-
tures of these antibiotics. In comparison with ristocetin,
pseudo aglyco-ristocetin (C) lacks the tetrasacharride
unit and the b-O-mannosyl group. The synthesis and
design of vancomycin-type antibiotics has been the
subject of numerous studies and the mode of action of
the vancomycin-type antibiotics is quite well under-
stood [5–7]. Common to all vancomycin-group antibi-
otics is that they bind to immature bacterial cell walls,
terminating cell-wall synthesis and ultimately leading
to the death of the bacteria. Even before the chemical
structure of vancomycin was elucidated Perkins
showed that the antibiotic binds selectively to bacterial
cell-wall mucopeptide precursors with a carboxytermi-
nal sequence terminating in -L-Lysyl-D-Alanyl-D-Ala-
nine [8]. Binding constants between vancomycin-group
antibiotics and cell-wall mimicking peptides, such as
N-acetyl-D-Alanyl-D-Alanine (acAA), have been deter-
mined using spectrophotometric methods [9–14], NMR
[15], and affinity capillary electrophoresis [16]. It is well
established that these binding constants vary for differ-
ent solvents [17] and with pH [18]. Recently, electros-
pray ionization (ESI) mass spectrometry has been ap-
plied to investigate vancomycin, ristocetin, and
teicoplanin antibiotics and their noncovalent complexes
with small bacterial cell-wall mimicking peptides [19–
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21]. ESI is a relatively soft ionization technique [22]
which allows the ionization and gentle phase transition
of intact macromolecules from solution into the vacuum
of a mass spectrometer. Even intact weakly bound
noncovalent complexes have been detected using this
ionization method [23, 24].
The detailed solution-phase structures of complexes
formed between vancomycin-group antibiotics and sev-
eral small bacterial cell-wall mimicking peptides have
been elucidated using NMR spectroscopy, in particular
using the nuclear Overhauser effect (NOE) [5, 12, 25,
26]. A schematic picture of the proposed aqueous
solution-phase structure of the complex of vancomycin
with acAA, adopted from Williams and Westwell [5], is
depicted in Figure 2. The interaction is based on hydro-
philic as well as hydrophobic interactions. Several hy-
drogen bonds are formed between the carboxylate
anion of the peptide and the amides of the peptide
backbone of the antibiotic. Other additional hydrogen
bonds are formed between the peptide and antibiotic,
securing the peptide in place. Hydrophobic interac-
tions, for instance, between the methyl groups of the
peptide and the aromatic rings of the antibiotic are
believed to promote the binding.
In recent years analogs of several noncovalent com-
plexes known to exist in solution have been detected in
the gas phase by ESI mass spectrometry. Gas-phase
structures of macromolecular ions have been probed by
gas-phase H/D exchange, e.g., for peptides [27] and
multiply protonated proteins such as cytochrome c [28]
and lysozyme [29]. Although, it has been shown that
complexes of vancomycin-group antibiotics with bacte-
rial cell-wall mimicking peptides can be detected in the
gas phase [19, 20], a largely unanswered question
remains as to whether the gas phase structures of these
complexes are similar to their well-characterized solu-
tion-phase structures. In this study we report an inves-
tigation into the gas-phase H/D exchange behavior of
vancomycin-group antibiotics, addressing in particular
whether and how complex formation with a bacterial
Figure 1. (A) Structures of vancomycin and eremomycin. (B) Structures of ristocetin and pseudo
aglyco-ristocetin. (C) Structures of N-acetyl-D-Alanyl-D-Alanine, N-acetyl-Glycyl-D-Alanine, and
N,N9-di-acetyl L-Lysyl-D-Alanyl-D-Alanine.
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cell-wall mimicking peptide changes the reactivity. Gas-
phase time-resolved H/D exchange behavior of doubly
protonated vancomycin (V), eremomycin (E), ristocetin
(R), and pseudo aglyco-ristocetin (C) ions is compared
with the H/D exchange observed for the noncovalent
complexes of latter antibiotics with the bacterial cell-
wall mimicking peptides acAA, N-acetyl-Glycyl-D-Ala-
nine (acGA), and N,N9-di-acetyl L-Lysyl-D-Alanyl-D-
Alanine (ac2KAA).
Experimental
The apparatus used was a Fourier transform ion cyclo-
tron resonance (FT-ICR) mass spectrometer (Bruker
Daltonics, Billerica) equipped with a shielded 9.4 tesla
superconducting magnet (Magnex Scientific, Abingdon,
UK), a cylindrical “infinity” ICR cell, and an external
ESI source (Analytica of Branford, Branford) and has
been described previously [30, 31]. The electrospray
solution flow rate was typically 30 mL/h. The electro-
spray cone voltage was kept at relatively low voltages
(below 40 V) to enhance detection of the noncovalent
complexes. Carbon dioxide was used as the drying gas
in the electrospray source. Typical electrospray solu-
tions were made up in a mixture of 49:49:2 % water,
acetonitrile, and acetic acid, respectively. The formation
of the noncovalent complexes in water/acetonitrile/
acetic acid solutions was verified by circular dichroism
measurements (data not shown). The solution phase
structure of the noncovalent complexes in a mixture of
49:49:2 % water, acetonitrile, and acetic acid might be
somewhat different from the schematic structure pre-
sented in Figure 2, as the binding in the complex is
known to be approximately a factor of 10 weaker under
these denaturing conditions [17, 21]. In the electrospray
solutions the concentration of the antibiotic was typi-
cally 20 mM, whereas the concentration of the peptide
were varied from 5 to 80 mM, and was optimized to
produce significant amounts of the antibiotic–peptide
complex ions. All solvents were HPLC grade, and used
without further purification. Vancomycin, ristocetin,
acAA, and ac2KAA were purchased from Sigma Chem-
icals (UK) and used without further purification. acGA
was purchased from Sigma with free N-termini, acety-
lated with acetic acid anhydride, and purified by ion-
exchange chromatography. Pseudo aglyco-ristocetin
was prepared by methanolysis of ristocetin and purified
by reverse-phase (C-18) HPLC.
Hydrogen/deuterium exchange experiments were
carried out with ND3 (98.8% atom D) which was
purchased from C/D/N/Isotopes (Canada). Table 1
lists the compounds together with their nominal
masses. Following external ion generation the ions were
transferred to, and trapped in, the FT-ICR cell. The
background pressure in the ICR cell was typically 2 3
10210 mbar. ND3 was leaked into the cell to a pressure
of 2 3 1028 mbar to investigate the H/D exchange
reactions. The precursor ions of interest, i.e., doubly
protonated antibiotic molecules or [antibiotic1peptide]
complexes, were mass-selectively trapped in the ion
trap prior to the reaction period, ejecting all other ions
using correlated sweep excitation/ejection fields [30,
32–34]. A H/D exchange reaction time varying from 0
to approximately 400 s was incorporated prior to ion
detection. Table 2 classifies the a priori exchangeable
hydrogens present in the antibiotics and the cell-wall
mimicking peptides.
Results
ESI
Using electrospray solutions consisting of 49:49:2 v/v %
water, acetonitrile, and acetic acid, respectively, the
antibiotics were detected predominantly as doubly pro-
tonated (5 doubly positively charged) species. The free
di- and tri-peptides were detected as singly protonated
molecules only. The noncovalent complexes between
the antibiotics and the cell-wall mimicking peptides
were predominantly detected as doubly protonated
molecules. The ESI mass spectrum of a mixture of
vancomycin (20 mM) and ac2KAA (40 mM), displayed in
Figure 2. Schematic representation of the solution-phase com-
plex between vancomycin and N-acetyl-D-Alanyl-D-Alanine,
adapted from [5].
Table 1. Molecular formulas and molecular masses of
antibiotics and peptides
Molecule Nominal mass (Da)
Vancomycin 1447
Eremomycin 1556
Ristocetin 2066
Pseudo-aglyco ristocetin 1302
N-acetyl-Glycyl-D-Alanine 188
N-acetyl D-Alanyl-D-Alanine 202
N,N9-di-acetyl L-Lysyl-D-Alanyl-D-Alanine 372
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Figure 3, shows isotopic clusters of ions with m/z
values of 724.7 ([V12H]21), 910.8 ([V1ac2KAA1
2H]21), and 1448.4 ([V1H]1). Additional, ion signals
can be attributed predominantly to fragments of van-
comycin. ESI mass spectra of mixtures of glycopeptide
antibiotics and bacterial cell wall analog peptides have
been reported previously [19–21] and the present ESI
mass spectra are quite similar.
Hydrogen/Deuterium Exchange
Vancomycin. When [V12H]21 ions were trapped in a
environment of gaseous ND3, it was observed that the
mass-to-charge ratio values of the detected ions in-
creased with time. This observed mass increase was
because of exchange reactions in which the ions replace
hydrogens for deuteriums. H/D exchange was the only
observed reaction. In Figure 4A the ESI mass spectra of
doubly protonated vancomycin are displayed as a func-
tion of the trapping time inside the FT-ICR cell which
contained gaseous ND3 (p 5 2.0 3 10
28 mbar). The
isotope distribution observed at a trapping time of 0 s
matched nicely the theoretically predicted isotope pat-
tern of [V12H]21 ions. From the spectra displayed in
Figure 4A it can be seen that the [V12H]21 ions had
exchanged up to seven hydrogens for deuteriums in
reactions with ND3 following a reaction time of 384 s.
In separate experiments the noncovalent complex
ions [V1acAA12H]21 and [V1ac2KAA12H]
21 were
reacted with ND3 under identical conditions. The only
reaction channel observed was H/D exchange. It was
found that the ionic antibiotic–peptide complexes re-
mained intact even at trapping times extending to 400 s.
In Figure 4B, C the ESI mass spectra of the [V1acAA1
2H]21 and [V1ac2KAA12H]
21 ions, respectively, are
displayed as a function of the trapping time inside the
FT-ICR cell which contained gaseous ND3 (p 5 2.0 3
1028 mbar). From the spectra displayed in Figure 4B
and 4C it can be seen that the [V1acAA12H]21 and
[V1ac2KAA12H]
21 ions have exchanged up to 12
hydrogens for deuteriums in reactions with ND3. The
extent of deuterium incorporation observed after a
reaction delay of 384 s for the three different systems:
[V12H]21, [V1acAA12H]21, and [V1ac2KAA12H]
21,
is summarized in Table 3.
Eremomycin. Eremomycin is structurally quite similar
to vancomycin [4, 35], although its solution-phase prop-
erties (and antibacterial activity) are different. One of
the most striking differences is the high dimerisation
constant of eremomycin, Kdim . 1 3 10
6 M21 [36],
whereas the vancomycin dimerization constant is below
103 M21 [36, 37]. In the ESI mass spectra of eremomycin
quite abundant ion signals were observed originating
from eremomycin dimers. In the present study we
focus, however, on the monomeric ions. Similar exper-
Table 2. Number of exchangeable hydrogens in studied ionic systems
Species Amide Amino Phenol Hydroxy Carboxyl Protons ¥Hex
[Vancomycin12H]21 8 3 3 6 1 2 23
[Eremomycin12H]21 8 5 36 6 1 2 25
[C12H]21 6 4 6 2 0 2 20
[Ristocetin12H]21 6 4 4 17 0 2 33
[ac-D-Ala-D-Ala1H]1 2 0 0 0 1 1 4
[di-ac-L-Lys-D-Ala-D-Ala1H]1 4 0 0 0 1 1 6
[V1acAA12H]21 10 3 3 6 2 2 26
[V1ac2KAA12H]
21 12 3 3 6 2 2 28
[E1acAA12H]21 10 5 3 6 2 2 28
[E1ac2KAA12H]
21 12 5 3 6 2 2 30
[C1acAA12H]21 8 4 6 2 1 2 23
[C1ac2KAA12H]
21 10 4 6 2 1 2 25
[R1acAA12H]21 8 4 4 17 1 2 36
[R1acGA12H]21 8 4 4 17 1 2 36
[R1ac2KAA12H]
21 10 4 4 17 1 2 38
Figure 3. ESI FT-ICR mass spectrum recorded from a 49/49/1%
water/acetonitrile/acetic acid mixture containing mixture of van-
comycin (20 mM) and N,N9-di-acetyl L-Lysyl-D-Alanyl-D-Alanine
(40 mM). The doubly protonated vancomycin ions and doubly
protonated antibiotic–peptide complex ions dominate the spec-
trum. The signal detected at m/z 5 1306 originates from singly
charged fragment ions formed by loss of part of the sugar groups
of vancomycin [20].
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Figure 4. (A) ESI mass spectra of doubly protonated vancomycin ions recorded following varying
reaction delays in an environment of gaseous ND3. (B) As in (A) for doubly protonated [vancomycin1
N-acetyl-D-Alanyl-D-Alanine] ions. (C) As in (A) for doubly protonated [vancomycin1N,N9-di-acetyl
L-Lysyl-D-Alanyl-D-Alanine] ions.
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iments as described above for vancomycin were per-
formed with eremomycin. In reactions with ND3 dou-
bly protonated eremomycin, and the corresponding
complexes with the cell-wall mimicking peptides, re-
acted exclusively via H/D exchange. The deuterium
content measured after reacting 384 s with ND3 for the
three different systems: [E12H]21, and [E1acAA1
2H]21, and [E1ac2KAA12H]
21, is summarized in Table
3.
Ristocetin. Mass spectra of [R12H]21 ions, recorded at
varying reaction times in the ICR cell, are shown in
Figure 5A. It was found that [R12H]21 ions reacted
with ND3 exclusively via H/D exchange, and ex-
changed within 48 s up to 12 hydrogens for deuteriums,
after which no significant successive exchange was
observed. Mass spectra of [R1acAA12H]21 ions, re-
corded at varying reaction times, are shown in Figure
5B. [R1acAA12H]21 ions reacted with ND3 via two
competing pathways. H/D exchange was one of the
pathways, the alternative pathway led to the formation
of adducts between the [R1acAA12H]21 ions and ND3.
The latter assignment was verified by accurate mass
measurement. The [R1acAA12H]21 ions exchanged
approximately 21 hydrogens for deuteriums after react-
ing for 384 s with ND3, which is 9 more than the free
[R12H]21 ions. At a similar reaction time the [R1acAA1
ND312H]
21 ions had exchanged approximately 19 hy-
drogens for deuteriums. In remarkable contrast, [R1
acGA12H]21 ions reacted only via a single pathway,
namely H/D exchange. Following a reaction time of
384 s these ions had exchanged approximately 24 hy-
drogen for deuteriums, which is 12 more than the
[R12H]21 ions. [R1ac2KAA12H]
21 ions reacted exclu-
sivelyviaH/Dexchange.Thespectraofthe[R1ac2KAA1
2H]21 ions are displayed in Figure 5C. The [R1ac2KAA1
2H]21 ions had exchanged approximately 24 hydrogens
for deuteriums after reacting for 384 s with ND3, which
is 12 more than the [R12H]21 ions. The extent of
deuterium incorporation observed for the [R12H]21,
[R1acAA12H]21, [R1aGA12H]21, and [R1ac2KAA1
2H]21 ions, after reacting with gaseous ND3 for 384 s, is
summarized in Table 3.
Pseudo aglyco-ristocetin. C is known to bind to cell-wall
precursor peptides, and often displays similar binding
affinities to ristocetin [12]. In contrast to ristocetin it was
found that the [C1ac2KAA12H]
21 ions exchanged,
even after 384 s reaction time, less hydrogens for
deuteriums than the free [C12H]21 ions. [C12H]21
and [C1ac2KAA12H]
21 ions exchanged approxi-
mately 10 and 8 hydrogens after 384 s reaction time,
respectively. [C1acAA12H]21 ions exchanged margin-
ally more hydrogens for deuteriums than the free
[C12H]21 ions. Table 3 summarizes the degree of
deuterium incorporation for all three studied systems
following a reaction delay of 384 s.
Free cell-wall mimicking peptides. The reactivity of the
unbound [acAA1H]1, [acGA1H]1, and [ac2KAA1H]
1
ions in reaction with ND3 was probed under identical
conditions, as described above for the antibiotic–pep-
tide complexes. It was observed that the [acAA1H]1,
[acGA1H]1, and [ac2KAA1H]
1 ions react with ND3
via two competing channels, i.e., H/D exchange and
adduct formation. After a reaction delay of 192 s [acAA1
H]1 and [acGA1H]1 had exchanged approximately 3.5
hydrogens for deuteriums, whereas [ac2KAA1H]
1 ions
had exchanged 5 hydrogens for deuteriums. The ND3
adduct was observed to have exchanged a similar
amount of hydrogens for deuteriums. Following a re-
action delay of 192 s the [peptide1ND31H]
1 ions were
the most abundant species.
Extent and Dynamics of H/D Exchange and
Adduct Formation
In principle, all the different sites in a molecule ion may
have different rates for H/D exchange depending pri-
marily on the gas-phase proton affinities and the acces-
sibility of the site. The observed rate is an average rate
for exchange, averaged over all exchangeable sites.
Calculation of the exchange rates and the average
deuterium content can be done by various mathemati-
cal methods, such as inverse matrix computation [38],
self-bound direct search optimization technique (such
as “pattern search”) [39], or derivative methods [40].
We have employed two different methods; an in house
developed constrained pattern search approach and the
maximum entropy optimized approach developed by
Zhang et al. [40]. It was found that both these methods
gave almost identical results. The algorithms produce a
probability for each step in the H/D exchange. We
average these numbers to produce the average degree
Table 3. Average degree of deuterium incorporation following H/D exchange with ND3 after a
reaction time of 384 s. The estimated plateau values, rounded to the nearest, higher integer, are
given in parentheses
Free D-Ala-D-Ala Gly-D-Ala L-Lys-D-Ala-D-Ala
Vancomycin 7.4 (8) 13.0 (14) 12.2 (14)
Eremomycin 10.2 (11) 15.1 (16) 15.3 (16)
Ristocetin 12.3 (13) 21.1 (25) 23.2 (25) 23.3 (25)
Pseudo aglyco-ristocetin 10.2 (11) 11.7 (12) 8.5 (9)
acAA 3.5 (4)
ac2KAA 5.0 (5)
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of deuteration. The average degree of deuteration is
calculated from each of the mass spectra recorded at
different reaction times. In Figure 6 the average deute-
rium content is shown for the [V12H]21, [V1acAA1
2H]21, and [V1ac2KAA12H]
21 ions as a function of the
reaction delay. As can be seen from Figure 6 [V12H]21
ions exchanged (within 12 s) the first seven hydrogens
very rapidly, after which the rate of exchange decreased
dramatically. In contrast, [V1acAA12H]21 ions ini-
tially reacted relatively slower. However, the exchange
reaction proceeds longer for these [V1acAA12H]21
ions and the degree of deuteration overhauls the degree
of deuteration of [V12H]21 ions. Figure 6 illustrates the
two important parameters that have to be distin-
guished: (a) the amount of rapid exchangable protons
that is equal to the “leveled-off” degree of deuterium
incorporation at long reaction times, which have been
summarized in Table 3, and (b) the kinetical features of
the H/D exchange revealed at shorter reaction times.
Figures 7, 8 and 9 are similar to Figure 6 and display the
varying degrees of deuterium incorporation for eremo-
mycin, ristocetin, and pseudo aglyco-ristocetin (and
their complexes with the peptides) as a function of
reaction time. Figure 10 show the kinetics for the H/D
exchange for the protonated cell-wall mimicking pep-
tides. Additionally, adduct formation was observed in
the reaction with ND3, but only for unbound peptide
ions and for [R1acAA12H]21 ions. In Figure 11 the
kinetics of adduct formation are given for these species.
Closer examination of the first parts of the kinetic
plots shown in Figures 6 to 8 reveal that in the first
period of the reaction with ND3 (reaction time ,25 s)
the average rates of H/D exchange were approximately
identical for [V12H]21 and [V1acAA12H]21. The rate
of H/D exchange for the [V1ac2KAA12H]
21 ions was
at the “early” stages of the exchange significantly
Figure 5. (A) ESI mass spectra of doubly protonated ristocetin
ions recorded following varying reaction delays in an environ-
ment of gaseous ND3. (B) As in (A) for doubly protonated
[ristocetin1N-acetyl-D-Alanyl-D-Alanine] ions. (C) As in (A) for
doubly protonated [ristocetin1N,N9-di-acetyl L-Lysyl-D-Alanyl-
D-Alanine] ions.
Figure 6. Average number of deuteriums incorporated in doubly
protonated ions of vancomycine, [vancomycin1N-acetyl-D-Ala-
nyl-D-Alanine], and [vancomycin1N,N9-di-acetyl L-Lysyl-D-Ala-
nyl-D-Alanine], as a function of the reaction delay. During the
reaction delay the ions were reacted with gaseous ND3 inside the
FT-ICR cell.
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slower. Figure 7 shows that [E12H]21 exchanged, at the
early stages of the reaction, faster than the [E1acAA1
2H]21 and [E1ac2KAA12H]
21 ions. Remarkably, Fig-
ure 8 reveals that initially [R12H]21 ions exchanged at
a similar rate as the [R1acGA12H]21 and [R1ac2KAA1
2H]21 ions, however, the [R1acAA12H]21 ions
showed a much slower initial rate, which is a contrast-
ing finding compared to vancomycin and its complexes
with these peptides.
Discussion
The gas-phase proton affinity of ND3 is approximately
854 kJ/mol [41]. The gas phase proton affinities of the
peptides, the antibiotics, and their complexes must be
higher than 854 kJ/mol as we do not observe any
proton transfer to ammonia to form free ND3H
1 ions.
The antibiotics, the cell-wall mimicking peptides, and
their complexes have a range of functional groups
which all have different “localized” gas-phase proton
affinities. Proton affinities of a number of amino acids
and small peptides have been measured, and are gen-
erally above 850 kJ/mol [41–43]. The site of gas-phase
protonation of peptides and proteins is a continuing
theme of debate. It is often assumed that the protona-
tion site of a peptide is on the nitrogen atom, when they
contain a free N-terminus, but there is also a variety of
evidence supporting the view that protonation at the
oxygen atom of the amide backbone can stabilize the
Figure 7. Average number of deuteriums incorporated in doubly
protonated ions of eremomycin, [eremomycin1N-acetyl-D-Ala-
nyl-D-Alanine], and [eremomycin1N,N9-di-acetyl L-Lysyl-D-Ala-
nyl-D-Alanine], as a function of the reaction delay. During the
reaction delay the ions were reacted with gaseous ND3 inside the
FT-ICR cell.
Figure 8. Average number of deuteriums incorporated in doubly
protonated ions of ristocetin, [ristocetin1N-acetyl-D-Alanyl-D-
Alanine], [ristocetin1N-acetyl-Glycyl-D-Alanine], and [ristocetin1
N,N9-di-acetyl L-Lysyl-D-Alanyl-D-Alanine], as a function of the
reaction delay. During the reaction delay the ions were reacted
with gaseous ND 3 inside the FT-ICR trap.
Figure 9. Average number of deuteriums incorporated in doubly
protonated ions of pseudo aglyco-ristocetin, [pseudo aglyco-
ristocetin1N-acetyl-D-Alanyl-D-Alanine], and [pseudo aglyco-
ristocetin1N,N9-di-acetyl L-Lysyl-D-Alanyl-D-Alanine], as a
function of the reaction delay. During the reaction delay the ions
were reacted with gaseous ND3 inside the cell.
Figure 10. Average number of deuteriums incorporated in the
protonated ions of N-acetyl-D-Alanyl-D-Alanine and N,N9-di-
acetyl L-Lysyl-D-Alanyl-D-Alanine, as a function of the reaction
delay. During the reaction delay the ions were reacted with ND3
inside the cell.
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protonated peptide by allowing formation of intramo-
lecular hydrogen bonds [44–46]. The peptides and
glycopeptide antibiotics have quite a few basic func-
tional groups, which can be classified as amino, amide,
phenolic, hydroxy, and carboxylic groups. In general,
the gas-phase proton affinities of these functional
groups decrease roughly in the order amino . amide .
carboxylic acid . hydroxy . phenol.
It has been established that gas-phase H/D exchange
occurs predominantly via a multiple well potential
energy surface with several possible intermediate pro-
ton bound complexes [46–52]. Within such a collision
complex, driven by the ion-dipole energy, the doubly
protonated antibiotic ions can transfer a proton to ND3
(forming ND3H
1 which remains bound in the collision
complex). The ND3H
1 unit in the collision complex can
subsequently backtransfer a deuteron instead of the
initial proton. ND3 has three deuteriums, so the possi-
bility exists that multiple H/D exchange occurs in a
single collision encounter [51]. H/D exchange rates
depend on the difference in proton affinity between the
two reactants (thermodynamic effect) but also on bar-
riers in the entrance and exit channels, for instance
induced by a tightly folded conformation of the ions
[46, 51]. H/D exchange reactions are sensitive to all
these effects as they probe directly the number of
kinetically and thermodynamically labile hydrogens.
The singly protonated peptide N-acetyl-D-Ala-D-Ala
contains two amide hydrogens, one carboxyl hydrogen
and one extra proton, attached to the molecule through
the ESI process. Therefore, [acAA1H]1 ions have four
labile hydrogens. The [acAA1H]1 ions exchanged
quite rapidly an average number of 3.5 hydrogens for
deuteriums (see Table 3), which corresponds to 88%
deuterium content considering all labile hydrogens. The
behavior of the [acGA1H]1 ions was very similar. The
[ac2KAA 1H]
1 ions exchange rapidly 85% of their
labile hydrogens. Similar average values (approximate-
ly 80%) for rapid deuterium incorporation were found
by Gard et al. [46] for analogous compounds such as
di-alanine and glycyl-alanine. For the protonated pep-
tides the H/D exchange reaction channel competed
with adduct formation. Adduct formation, although
studied at significantly higher pressures, has been re-
ported before for protonated alanine and protonated
alanylalanine [50], and many other peptides and pro-
teins [53]. Summarizing, the protonated peptide ions
exchange quite rapidly up to 80%–90% of their labile
hydrogens for deuteriums in reactions with ND3, addi-
tionally these ions form adducts with ND3. These
experimental findings are in agreement with literature
data on related compounds. Below the question is
addressed as to whether the observed rapid H/D
exchange of almost all labile hydrogens, and the facile
adduct formation, are also observed when these cell-
wall mimicking peptides are complexed to the antibi-
otics.
The studied antibiotics all contain a different number
of labile hydrogens (see Table 2). Vancomycin and
eremomycin are structurally closely related, see Figure
1. The total number of labile hydrogens are 23 and 25 in
doubly protonated vancomycin and eremomycin, re-
spectively (see Table 2). It was observed that both of
these species exchanged only up to 35% of their ex-
changable hydrogens for deuteriums in reactions with
ND3. The fact that eremomycin ions exchanged on
average two more hydrogens than the vancomycin ions
may indicate that the two amino hydrogens present on
the 4-epi-vancosamine sugar unit present in eremomy-
cin are involved in the rapid exchange. From Tables 2
and 3 it can be concluded that doubly protonated
vancomycin and eremomycin do not even exchange all
their amino and amide hydrogens in reactions with
ND3. Some of these amino and/or amide hydrogens are
unexpectedly immobile, possibly because they are in-
volved in intramolecular hydrogen bonding (see be-
low).
[C12H]21 ions exchanged quite rapidly approxi-
mately 11 (i.e., 55% degree of deuterium incorporation)
hydrogens for deuteriums, before the H/D exchange
rate leveled off. For the [R12H]21 ions the number of
hydrogens that exchanged rapidly was 13, which is
only 40% of the total number of labile hydrogens (see
Table 2). Compared to pseudo-aglycoristocetin, ristoce-
tin contains quite a few more (15) hydroxy-hydrogens
(see Figure 1). With the number of fast exchanging
hydrogens for [C12H]21 and [R12H]21 ions being
quite similar (11 and 13, respectively) it might be
concluded that the extra hydroxy-hydrogens present in
ristocetin are not involved significantly in the H/D
exchange for these two species.
Summarizing, the doubly protonated antibiotics ex-
changed in reactions with ND3 only a limited amount
(approximately 35%–40%) of their labile hydrogens
rapidly. The immobility of the other a priori labile
Figure 11. Kinetics of the adduct formation reaction for the
protonated ions N-acetyl-D-Alanyl-D-Alanine and N,N9-di-acetyl
L-Lysyl-D-Alanyl-D-Alanine, and the doubly protonated [ristocetin1
N-acetyl-D-Alanyl-D-Alanine] and [ristocetin1N,N9-di-acetyl L-
Lysyl-D-Alanyl-D-Alanine] ions in reactions with ND3. M in the
ratio (M1ND3)/M indicates the ion of interest (i.e., protonated
peptide or doubly protonated antibiotic–peptide complexes).
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hydrogens might be caused by a mixture of thermody-
namic (i.e., energetically not accessible) and kinetic
effects (such as induced by steric hindrance and/or
hydrogen bonding). As will be discussed in more detail
below, the experimental data on the H/D exchange of
the doubly protonated noncovalent complexes suggest
that the role of kinetic effects is significant.
For a gas-phase structure resembling the known
solution-phase structure of the antibiotic–peptide com-
plexes it might be suggested that the intermolecular
hydrogen bonds formed upon complexation make sev-
eral of the labile hydrogens less accessible for H/D
exchange. The antibiotic–peptide complex should then
exchange fewer hydrogens than the sum of exchange-
able hydrogens in the antibiotic and the peptide. As can
be seen in Figure 2, in solution the antibiotic–peptide
complexes have a zwitterionic charge distribution, i.e.,
the peptide ligand is deprotonated (carboxylate anions)
and the amino groups present in the antibiotics are
protonated (ammonium cations). In solution at neutral
pH the eremomycin–peptide and the ristocetin–peptide
complexes have a positive charge (11), whereas the
vancomycin–peptide complexes are neutral.
The two most basic sites in vancomycin are the
N-terminal amino group and the amino group at the
vancosamyl residue (see Figure 1). It is, therefore,
reasonable to assume that those two groups will be
protonated. It is known, however, that in the gas-phase
protons are not necessarily located at the most basic
sites [54]. The main question is, however, whether the
carboxylate anions retain their negative charge in the
gas phase and thereby retain their specific interaction
with the binding pocket. If the peptide carboxylic group
is indeed deprotonated the additional proton has to be
located elsewhere, possibly on the amide oxygens of the
peptide backbone. Such a structure would lead to a
zwitterionic charge distribution, which is probably en-
ergetically unfavorable without solvent stabilization
[51]. There are, however, some indications that “salt
bridges” can stabilize gas phase structures, e.g., the gas
phase structure of singly protonated bradykinin is
considered to be a zwitterion [55].
In the vancomycin–peptide complex it is structurally
difficult to have the carboxylate anion of the peptide
close to an ammonium ion without leaving the binding
pocket. Furthermore, the proton affinity of the vanco-
mycin amino groups might be too low to make a salt
bridge structure energetically favorable. Consequently,
it is assumed that the carboxylate group in the vanco-
mycin–peptide complexes will be most likely neutral
(COOH) in the gas phase. Independent collision-in-
duced dissociation experiments also suggest that the
carboxylate anion is protonated (neutral COOH) [56]. A
neutral carboxylate group will lead to a considerable
weakening of the hydrogen bonds normally formed
between the negatively charged carboxylate group and
the amide hydrogens in the antibiotic peptide back-
bone. Retention of the ligand in the binding pocket is
then less favorable and alternative structures have to be
considered. Summarizing, the positive charge of the
noncovalent complexes in the gas phase, because of the
double protonation by the ESI process, might have
considerable effects on the structures.
Complex formation of vancomycin with the cell-wall
mimicking peptides acAA and ac2KAA leads to an
increase of the number (approximately 6) of incorpo-
rated deuteriums. Whereas, doubly protonated vanco-
mycin exchanges only 33% of its labile hydrogens for
deuteriums these numbers increase to approximately
55% and 50% for its complexes with the acAA and
ac2KAA peptides, respectively. As the neutral acAA
and ac2KAA peptides have only three and five labile
hydrogens, respectively, the increased number of rapid
exchanging hydrogens has to come at least partly from
labile hydrogens present in the antibiotic, which did not
exchange in the uncomplexed doubly protonated van-
comycin. Doubly protonated vancomycin complexes
with acAA and ac2KAA do not react by adduct forma-
tion with ND3, a reaction observed for the free proton-
ated peptides (see Figure 11). The nonoccurrence of
these adduct-forming reactions might imply that the
cell-wall precursor peptides are not protonated in the
complexes. Similar behavior as observed for the com-
plexes of vancomycin is observed for the complexes of
eremomycin (see Table 3). Complex formation seems to
open up a few additional sites for H/D exchange. This
relative increase of the number of rapidly exchangable
hydrogens is even more remarkable in the case of
ristocetin. Doubly protonated ristocetin exchanges up
to 40% of its labile hydrogens for deuteriums. The
complexes of ristocetin with acGA, acAA, or ac2KAA
exchange quite rapidly up to 25 hydrogens for deuteri-
ums (or approximately 70% of its labile hydrogens),
almost doubling the number of exchanged hydrogens
when compared to uncomplexed ristocetin. The com-
plex formation seems to work for these systems as a
catalyst for H/D exchange. The complex formation
with the peptide must open several new sites for H/D
exchange. From Tables 2 and 3 it may be concluded that
the exchange in the ristocetin–peptide complexes must
involve quite a few of the hydroxy hydrogens as well
(which were thought to be quite unreactive in the
uncomplexed [R12H]21 ions).
The remarkable H/D exchange behavior of the anti-
biotic–peptide complexes of vancomycin, eremomycin,
and ristocetin suggest that in the gas phase a significant
proportion of the peptide ligands might be located
external to the “solution-phase” binding pocket. The
increased H/D exchange reactivity might then be
caused by the fact that the peptide is involved in
solvating the ammonium ionic sites in the antibiotics.
Similar solvation effects have been suggested for sol-
vated “onium” ions in H/D exchange studies by Camp-
bell et al. [51]. In the ristocetin–peptide complexes it
appears that the tetrasaccharide unit is directly in-
volved in the peptide interaction, which is a further
indication that the peptide might be located outside the
binding pocket. The odd-one out appears to be pseudo
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aglyco-ristocetin. Upon complexation with acAA the
number of hydrogens exchanged in [C1acAA12H]21
with respect to [C12H]21, increases, but only by 1 (see
Table 3), complexation with ac2KAA gives rise to an
apparent decrease of exchanging hydrogens from 11 (or
55%) in [C12H]21 to 9 (or 36%) in the [C1acAA1
2H]21 ions. Additionally, in contrast to ristocetin, none
of the investigated complexes of pseudo aglyco-ristoce-
tin form adducts with ND3. The data presented here
suggest that the gas-phase structures of the noncovalent
complexes of the two antibiotics ristocetin and pseudo
aglyco-ristocetin with the cell-wall mimicking peptides
are different.
The relatively slow initial H/D exchange observed
for some of the complexes, notably vancomycin with
ac2KAA, ristocetin with acAA, and both noncovalent
complexes of eremomycin, may be explained by tightly
folded conformations of the complexes in which some
of the “basic” hydrogens are involved in the noncova-
lent complex formation. A mechanism, as suggested
above, in which the peptides and/or antibiotics “sol-
vate” each others’ basic sites seems plausible. However,
from the present findings definite reasons as to why
some of the, at first glance, very similar antibiotic–
peptide complexes would be more folded or solvated
cannot be provided. An alternative explanation for the
apparent slower H/D exchange observed in some of the
complexes might be that they have different gas-phase
proton affinities. Although it is conceivable that the
antibiotics vancomycin, eremomycin, ristocetin, and
pseudo aglyco-ristocetin have different gas-phase pro-
ton affinities, it is less likely that the proton affinities of
one of these antibiotics complexed with different pep-
tides differ significantly. Therefore, it is suggested that
the most likely explanation of the observed different
chemical behavior of the structurally related noncova-
lent complexes is differences in higher-order structures.
This statement is further supported by the data on
the complexes of ristocetin with acGA and acAA. The
sole differences in primary structures of these two
complexes occurs in the dipeptides by the substitution
of an alanine with a glycine, which corresponds to a
substitution of a methyl by a hydrogen. The solution-
phase binding constants for ristocetin with acGA and
acAA are quite similar [9, 21]. Therefore, it is quite
remarkable that the gas-phase reactivity of the [R1
acGA12H]21 and [R1acAA12H]21 ions is found to be
different. With a high degree of confidence it can be
assumed that the gas-phase proton affinities of the
ristocetin complexes with acGA and acAA are similar.
One of the differences is of course that acAA has two
chiral centers, whereas acGA has only one. The extra
methyl group present in acAA may induce some steric
hindrance hampering the formation of a similar com-
plex as occurring for acGA. It is encouraging that
gas-phase H/D exchange turns out to be sensitive to
these subtle changes.
Conclusions
Doubly protonated vancomycin-group antibiotics and
their doubly protonated noncovalent complexes with
cell-wall precursor peptides have been studied using
gas-phase H/D exchange reactions with ND3 inside the
ion trap of a 9.4 tesla FT-ICR mass spectrometer. The
free antibiotics exchanged only a small part of the labile
hydrogens in reactions with ND3 (e.g., approximately
40% for ristocetin). In general, complexation with the
peptides increased this percentage considerably (e.g.,
approximately 70% of the hydrogens is exchanged in
case of the complex of ristocetin with acGA), although
for one of the investigated systems a small decrease was
observed (pseudo aglyco-ristocetin with ac2KAA). The
increase in the number of exchanged hydrogens in the
antibiotic–peptide complexes suggests that the peptide
operated as a sort of catalyst for H/D exchange. It is
proposed that the gas-phase structures of the antibiotic–
peptide complexes might differ from the well-charac-
terized solution-phase structures. The present results
indicate that in the gas phase many of the cell-wall
precursor peptides do not bind (exclusively) to the
characteristic solution-phase binding pocket. Subtle
changes in primary structures of the antibiotics and/or
the peptides were reflected in the chemical behavior of
the noncovalent complexes. For a full explanation of the
observed remarkable H/D exchange behavior more
detailed information is required about the gas-phase
structures of the investigated species. The studies pro-
vide, however, further evidence that gas-phase H/D
exchange is a very promising and powerful technique,
which can be used to probe minor changes in gas-phase
structures.
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